BREAKING
Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 9 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 11 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 11 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 23 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 24 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 1 day ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 1 day ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 1 day ago Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 9 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 11 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 11 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 23 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 24 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 1 day ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 1 day ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 1 day ago
ADVERTISEMENT
Market News

Earnings Summary: Highlights of Cardinal Health’s (CAH) Q4 2023 results

Pharmaceuticals distributor Cardinal Health (NYSE: CAH) announced financial results for the fourth quarter of 2023, reporting higher revenues and adjusted profit. Revenues increased 13% year-over-year to $53.5 billion in the final three months of fiscal 2023 Fourth-quarter operating earnings came in at $137 million, sharply higher than the $36 million reported a year earlier The […]

$CAH August 15, 2023 1 min read

Pharmaceuticals distributor Cardinal Health (NYSE: CAH) announced financial results for the fourth quarter of 2023, reporting higher revenues and adjusted profit.

  • Revenues increased 13% year-over-year to $53.5 billion in the final three months of fiscal 2023
  • Fourth-quarter operating earnings came in at $137 million, sharply higher than the $36 million reported a year earlier
  • The company reported a net loss of $64 million or $0.25 per share for Q4, compared to a profit of $138 million or $0.50 per share last year
  • On an adjusted basis, it was a profit of $1.55 per share, compared to $1.05 per share in the same quarter of 2022
  • The Pharmaceutical segment profit increased 12% to $504 million and Medical segment profit rose to $82 million
  • The company generated both operating cash flow and adjusted free cash flow of $2.8 billion in Q4
  • The management raised its fiscal 2024 adjusted EPS guidance to the range of $6.50 to $6.75, from $6.45-$6.70
ADVERTISEMENT